Validity of an adaptation of the Framingham cardiovascular risk function:: the VERIFICA study

被引:214
作者
Marrugat, Jaume
Subirana, Isaac
Comin, Eva
Cabezas, Carmen
Vila, Joan
Elosua, Roberto
Nam, Byung-Ho
Ramos, Rafel
Sala, Joan
Solanas, Pascual
Cordon, Ferran
Gene-Badia, Joan
D'Agostino, Ralph B.
机构
[1] IMIM, Lipids & Cardiovasc Epidemiol Unit, Barcelona 08003, Spain
[2] Inst Catala Salut, Barcelona, Spain
[3] Fundacio Gol & Gurina, Barcelona, Spain
[4] Autonomous Univ Barcelona, E-08193 Barcelona, Spain
[5] Hosp Girona Josep Trueta, Serv Cardiol, Girona, Spain
[6] Hosp Girona Josep Trueta, Unitat Coronaria, Girona, Spain
[7] Inst Catala Salut, Unitat Docent Med Familia Girona, Barcelona, Spain
[8] Univ Barcelona, Consorci Atencio Primaria Eixample, Barcelona, Spain
[9] Boston Univ, Boston, MA 02215 USA
[10] Framingham Heart Dis Epidemiol Study, Boston, MA USA
关键词
CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY-RATES; POPULATION; SPAIN; MEN; CHOLESTEROL; VALIDATION; PREVENTION; PREDICTION;
D O I
10.1136/jech.2005.038505
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: To assess the reliability and accuracy of the Framingham coronary heart disease (CHD) risk function adapted by the Registre Gironi del Cor (REGICOR) investigators in Spain. Methods: A 5-year follow-up study was completed in 5732 participants aged 35-74 years. The adaptation consisted of using in the function the average population risk factor prevalence and the cumulative incidence observed in Spain instead of those from Framingham in a Cox proportional hazards model. Reliability and accuracy in estimating the observed cumulative incidence were tested with the area under the curve comparison and goodness-of-fit test, respectively. Results: The Kaplan-Meier CHD cumulative incidence during the follow-up was 4.0% in men and 1.7% in women. The original Framingham function and the REGICOR adapted estimates were 10.4% and 4.8%, and 3.6% and 2.0%, respectively. The REGICOR-adapted function's estimate did not differ from the observed cumulated incidence ( goodness of fit in men, p = 0.078, in women, p = 0.256), whereas all the original Framingham function estimates differed significantly (p < 0.001). Reliabilities of the original Framingham function and of the best Cox model fit with the study data were similar in men (area under the receiver operator characteristic curve 0.68 and 0.69, respectively, p = 0.273), whereas the best Cox model fitted better in women (0.73 and 0.81, respectively, p < 0.001). Conclusion: The Framingham function adapted to local population characteristics accurately and reliably predicted the 5-year CHD risk for patients aged 35-74 years, in contrast with the original function, which consistently overestimated the actual risk.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 29 条
[1]  
ARTAUDWILD SM, 1993, CIRCULATION, V88, P2271
[2]   Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study [J].
Brindle, P ;
Emberson, J ;
Lampe, F ;
Walker, M ;
Whincup, P ;
Fahey, T ;
Ebrahim, S .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7426) :1267-1270A
[3]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[4]   Validation of the Framingham Coronary Heart Disease prediction scores - Results of a multiple ethnic groups investigation [J].
D'Agostino, RB ;
Grundy, S ;
Sullivan, LM ;
Wilson, P .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :180-187
[5]  
D'Agostino RB, 2004, HANDB STAT, V23, P1
[6]   European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice [J].
De Backer, G ;
Ambrosioni, E ;
Borch-Johnsen, K ;
Brotons, C ;
Cifkova, R ;
Dallongeville, J ;
Ebrahim, S ;
Faergeman, O ;
Graham, I ;
Mancia, G ;
Cats, VM ;
Orth-Gomér, K ;
Perk, J ;
Pyörälä, K ;
Rodicio, JL ;
Sans, S ;
Sansoy, V ;
Sechtem, U ;
Silber, S ;
Thomsen, T ;
Wood, D .
EUROPEAN HEART JOURNAL, 2003, 24 (17) :1601-1610
[7]  
EVANS JMM, 2002, BMJ-BRIT MED J, V324, P1
[8]   Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J].
Haffner, SM ;
Lehto, S ;
Rönnemaa, T ;
Pyörälä, K ;
Laakso, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) :229-234
[9]   Framingham risk function overestimates risk of coronary heart disease in men and women from Germany -: results from the MONICA Augsburg and the PROCAM cohorts [J].
Hense, HW ;
Schulte, H ;
Löwel, H ;
Assmann, G ;
Keil, U .
EUROPEAN HEART JOURNAL, 2003, 24 (10) :937-945
[10]   Statins for primary prevention: at what coronary risk is safety assured? [J].
Jackson, PR ;
Wallis, EJ ;
Haq, IU ;
Ramsay, LE .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :439-446